AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03916536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium Laser
Description: Thulium laser enucleation of large sized prostate
Study NCT03916536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar diathermy
Description: Bipolar enucleation of large sized prostate
Study NCT01748188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
Study NCT01748188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
Study NCT04533451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02712580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: First investigational device
Description: The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
Study NCT02712580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Second investigational device
Description: The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
Study NCT02712580 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ES Wetling W200 Placebo with white light
Description: The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
Study NCT02712580 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ES Wetling W200 Placebo with red light
Description: The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
Study NCT02643355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study NCT02643355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Study NCT03868956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colour doppler ultrasound with or without D-dimer test
Description: * Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment
Study NCT01748188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT03750227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03750227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03750227 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT01748188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
Study NCT01748188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
Study NCT03750227 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample, tissue and CSF sample collection
Study NCT03750227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample, tissue and CSF sample collection
Study NCT03345563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Mind Training (BMT)
Description: Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
Study NCT03345563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Training (BT):
Description: Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
Study NCT03345563 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care (UC)
Description: Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
Study NCT03465579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic MRI
Description: multi-parametric pelvic MRI
Study NCT01748188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
Study NCT01748188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
Study NCT01454128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: 36 session supervised exercise intervention
Study NCT01454128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 36 session supervised exercise intervention
Study NCT03079934 — intervention group
Intervention type: DEVICE
Intervention: Absorb-BVS
Description: BVS patients undergoing optical coherence tomography examination at follow-up
Study NCT01716039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX 12.5
Description: once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab
Study NCT01716039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX 25
Description: once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab
Study NCT01716039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects will receive 18 weekly doses of adalimumab
Study NCT01716039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Subjects will receive 18 weekly doses of adalimumab
Study NCT03155087 — intervention group
Intervention type: DRUG
Intervention: Metformin
Study NCT02895672 — intervention group
Intervention type: DRUG
Intervention: GLP-1 therapy
Description: The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
Study NCT04345029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement consumption
Description: The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days.
Study NCT04345029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement consumption
Description: The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days.
Study NCT01015495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
Study NCT01087658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Per os
Study NCT01087658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Magnesium
Description: Intravenous
Study NCT01087658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and Magnesium
Description: Intravenous
Study NCT03517839 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle trainig
Description: Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
Study NCT03517839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainig
Description: Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
Study NCT00426816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: Active compound at doses of 10mg, 30mg and 60mg
Study NCT00426816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match SB-649868
Study NCT00776594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
Study NCT00776594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50mg orally daily for 6 months
Study NCT00776594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
Study NCT01196468 — intervention group
Intervention type: OTHER
Intervention: HIV test (serological or salivary)
Description: An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition
Study NCT01196468 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
Study NCT02155868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction rSO2 desaturation.
Description: Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood \< 35 mmHg; mean arterial pressure \< 60 mmHg; central venous pressure > 10 mmHg; cardiac index \< 2.0 l/min/m2; mixed venous oxygen saturation \< 60%; hemoglobin \< 65 g/L during cardiopulmonary bypass or hemoglobin \< 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption.
Study NCT02155868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study NCT00053976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab
Study NCT00053976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT01850524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study NCT01850524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study NCT00053976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Study NCT00053976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04308239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
Study NCT04308239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago Balance Training
Description: Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
Study NCT03252444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conscious control
Description: Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
Study NCT03252444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conscious control+biofeedback
Description: In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
Study NCT00113672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase healthy activity and increase healthy eating
Description: Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
Study NCT00113672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease unhealthy activity and increase healthy eating
Description: Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
Study NCT00113672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase physical activity and decrease unhealthy eating
Description: Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
Study NCT00113672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease sedentary activity and decrease unhealthy eating
Description: Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
Study NCT02744495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
Study NCT02744495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
Study NCT04034719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portage scarf
Description: Parents will be carried their newborn with the portage scarf provided by the department.
Study NCT04034719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual practice
Description: Parents will be carried their newborn as their usual practice.
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Tablets, Oral, 15-45 mg, as needed (12 months LT)
Study NCT00327015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, Oral, 15-45 mg, as needed (12 months LT)
Study NCT03465579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-PSMA PET/CT
Description: 68Ga-PSMA PET/CT
Study NCT01850524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide capsules.
Study NCT01850524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide capsules.
Study NCT03785002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: 24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
Study NCT03785002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
Study NCT03785002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein intake
Description: Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
Study NCT03785002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein intake
Description: Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
Study NCT03222102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phasix mesh
Description: After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
Study NCT03428477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl
Description: Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
Study NCT00774644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Study NCT03428477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day
Study NCT03904589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life assessment
Description: Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
Study NCT02552303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia.
Study NCT02552303 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia.
Study NCT02552303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Active medication